3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Recurrence
1
Multiple Myeloma
1
Genetic Diseases, Inborn
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Dexamethasone
112
Bortezomib
61
Lenalidomide
49
Cyclophosphamide
49
Calcium Dobesilate
43
pomalidomide
32
Melphalan
31
fludarabine
25
Filgrastim
25
carfilzomib
22
fludarabine phosphate
21
daratumumab
20
Granulocyte Colony-Stimulating Factor
16
Whole-Body Irradiation
15
Antilymphocyte Serum
15
dexamethasone acetate
14
Mycophenolic Acid
14
Thalidomide
13
Tacrolimus
13
Cyclosporine
13
Busulfan
13
Peripheral Blood Stem Cell Transplantation
12
ixazomib
11
dexamethasone 21-phosphate
10
auricularum
10
pembrolizumab
9
Radiotherapy
9
Etoposide
9
belantamab mafodotin
8
Rituximab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Multiple Myeloma
×
Clinical Trials, Phase II as Topic
×
Clear all
NCT03683277
2025-02-19
IFM2014-01
Intergroupe Francophone du Myelome
Phase 2
Terminated
26 enrolled